Overview

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancerNMIBC after Bacillus Calmette-GuerinBCG failure and to assess the preliminary efficacy.
Phase:
PHASE1
Details
Lead Sponsor:
Zhuhai Beihai Biotech Co., Ltd
Treatments:
Docetaxel